drugset / Trial / NCT00808002
Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine
RandomizedParallel-groupOpen-labelTreatment
Summary
The intensification with maraviroc in recently HIV-1-infected patients of a preferred gold-standard triple therapy composed of raltegravir plus tenofovir/emtricitabine could accelerate the decay of the HIV-1 reservoir in latently infected cells established early in HIV-1 infection. This could provide further insight into this area, decrease the size of latent reservoir, and translate into clinical benefits for patients.
Timeline
- Start
- 2009-02
- Primary completion
- 2011-11
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Maraviroc | Other / unclassified | 300 mg | — |
| Background | Raltegravir | Other / unclassified | 400 mg | — |
| Background | Tenofovir | Small molecule | 300 mg | — |
| Background | emtricitabine | Other / unclassified | 200 mg | — |